



**ASAP VERSION USED**

This project was supported by Grant No. G1299ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government.

© 2014 Research is current as of March 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or [hgray@namsdl.org](mailto:hgray@namsdl.org) with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

State	Version
Alaska	4.1
Alabama	4.1
Arkansas	4.2
Arizona	3.0
California	4.1
Connecticut	3.0
Colorado	4.2
Delaware	4.2
Florida	4.2
Georgia	4.2
Guam	4.1
Hawaii	4.1 moving to 4.2
Iowa	4.1
Idaho	4.1
Illinois	4.1
Indiana	4.1 moving to 4.2 in 2014
Kansas	4.1
Kentucky	4.1 will require 4.2 eff. 7/1/2014
Louisiana	1995 moving to 4.2 in mid-2014
Maryland	4.2
Massachusetts	4.1
Maine	4.2
Michigan	4.1 requested 4.2
Minnesota	4.1
Mississippi	3.0
Montana	4.1
Nebraska	HL-7 (non-ASAP)
New Jersey	4.1 mandating 4.2 by 8/2014
Nevada	3.0
New York	4.2
New Mexico	4.1
North Carolina	4.2
North Dakota	4.1 moving to 4.2
Ohio	4.1
Oklahoma	4.1
Oregon	4.1
Pennsylvania	4.1 moving to 4.2
Rhode Island	1995 requested 4.2
South Carolina	4.2
Tennessee	4.1
Texas	1995 and 4.1
Utah	1995
Virginia	4.1
Washington	4.2
Wisconsin	4.2
West Virginia	4.2
Wyoming	1995 requested 4.2